| Literature DB >> 22510223 |
Li-Hui Huang1, Luo Zhang, Ruo-Yan Gai Tobe, Fang-Hua Qi, Long Sun, Yue Teng, Qing-Lin Ke, Fei Mai, Xue-Feng Zhang, Mei Zhang, Ru-Lan Yang, Lin Tu, Hong-Hui Li, Yan-Qing Gu, Sai-Nan Xu, Xiao-Yan Yue, Xiao-Dong Li, Bei-Er Qi, Xiao-Huan Cheng, Wei Tang, Ling-Zhong Xu, De-Min Han.
Abstract
BACKGROUND: Neonatal hearing screening (NHS) has been routinely offered as a vital component of early childhood care in developed countries, whereas such a screening program is still at the pilot or preliminary stage as regards its nationwide implementation in developing countries. To provide significant evidence for health policy making in China, this study aims to determine the cost-effectiveness of NHS program implementation in case of eight provinces of China.Entities:
Mesh:
Year: 2012 PMID: 22510223 PMCID: PMC3353179 DOI: 10.1186/1472-6963-12-97
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Figure 1The tree model for cost-effectiveness of two screening strategies (universal screening and targeted screening).
Figure 2The map of study sites including Beijing (☆), Shandong, Hebei, Henan, Jiangxi, Zhejiang, Guangxi and Guangdong.
Parameter values and plausible ranges for probability variables used in the baseline and sensitivity analysis
| Items | Baseline | Range for sensitivity analysis | References |
|---|---|---|---|
| High-risk infants | 7% | 6-8% | [ |
| Prevalence in all live-born | 0.30% | 0.2-0.4% | [ |
| Prevalence in high risk infants | 3.00% | 1.15-3.59% | [ |
| Sensitivity | 95% | 90-100% | [ |
| Specificity | 95% | 90-100% | [ |
| Coverage | 60% | 15-99% | [ |
| Diagnosis rate | 50% | 20-95% | [ |
| Intervention rate | 50% | 10-95% | [ |
Parameter values and plausible ranges for cost estimates per case used in the baseline and sensitivity analysis (Int $)
| Items | Hearing screening method | Baseline | Ranges for sensitivity analysis | |
|---|---|---|---|---|
| Minimum | Maximum | |||
| Screening | ||||
| Program costs | ||||
| Capital costs | OAE | 240,813,700 | 170,712,610 | 307,291,540 |
| OAE+AABR | 429,951,870 | 322,027,570 | 559,461,040 | |
| Recurrent costs | OAE | 150 | 100 | 200 |
| OAE+AABR | 230 | 130 | 360 | |
| Patient costs | 30 | 10 | 50 | |
| Diagnosis | ||||
| Program costs | ||||
| Capital costs | 15,950,600 | 11,014,773 | 21,467,600 | |
| Recurrent costs | 240 | 130 | 360 | |
| Patient costs | 170 | 90 | 310 | |
| Intervention | ||||
| Program costs | ||||
| Capital costs | 13,829,240 | 12,430,260 | 15,554,540 | |
| Recurrent costs | 290 | 200 | 440 | |
| Patient costs | 22,690 | 18,860 | 29,140 | |
Abbreviation: Otoacoustic emission (OAE); Automated auditory brainstem response (AABR)
Summary of estimates for long-term costs saving
| Items | long-term costs saving (Int $) | |
|---|---|---|
| Untreated children with PCEHI | Treated Children with PCEHI | |
| Medical services | ||
| For cases to fit hearing aid | 1,960 | 1,960 |
| For cases to fit cochlear implant | 40,000 | 40,000 |
| Special education | 42,300 | 38,070 |
| Rehabilitation | 82,400 | 20,600 |
| Total | 166,660 | 100,630 |
Basic information of study sites
| Provinces | Beijing | Shandong | Hebei | Zhejiang | Guangdong | Henan | Jiangxi | Guangxi |
|---|---|---|---|---|---|---|---|---|
| Populationa | 16,330,000 | 93,670,000 | 69,430,000 | 50,600,000 | 94,490,000 | 93,600,000 | 4,368,000 | 47,680,000 |
| Birth rate (per 1,000)a | 8.32 | 11.11 | 13.33 | 11.26 | 11.96 | 11.26 | 13.86 | 14.19 |
| No. of live births per yeara | 135,866 | 1,040,674 | 925,502 | 1,053,936 | 1,130,100 | 1,053,936 | 605,405 | 676,579 |
| GDP per capita (Int$)b | 16,644.25 | 7,951.80 | 5,684.11 | 10,698.20 | 9,479.99 | 4,578.86 | 3,612.58 | 3,590.28 |
| Life expectancya | 76.1 | 73.92 | 72.54 | 74.7 | 73.27 | 71.54 | 68.95 | 71.29 |
| Development statusc | Developed | Developed | Developed | Developed | Developed | Moderately developed | Moderately developed | Less developed |
| No. of screening facilitiesa | 548 | 1,402 | 1,296 | 722 | 1,154 | 1,341 | 602 | 553 |
| No. of diagnosis centersa | 6 | 17 | 11 | 11 | 21 | 17 | 11 | 14 |
| No. of rehabilitation facilitiesa | 12 | 14 | 8 | 8 | 15 | 10 | 6 | 5 |
| Coverage rated | 97.8% | 83.3% | 91.3% | 83.3% | 97.0% | 24.5% | 30.5% | 50.2% |
| Diagnosis rated | 97.4% | 68.3% | 60.0% | 60.0% | 75.0% | 30.2% | 48.2% | 21.4% |
| Intervention rated | 77.1% | 72.5% | 76.1% | 70.0% | 75.0% | 23.8% | 33.3% | 23.9% |
| Proportion of benefit population | 73.4% | 41.3% | 41.7% | 35.0% | 54.6% | 1.8% | 4.9% | 2.6% |
Data source:
a: Ministry of Health of the People's Republic of China [17].
b: International Monetary Fund [39].
c: Ministry of Health of the People's Republic of China [35].
d: Provincial data
Implementation costs, health effects and cost-effectiveness of different NHS strategies in eight provinces
| Items | Guangxi | Jiangxi | Henan | Guangdong | Zhejiang | Hebei | Shandong | Beijing |
|---|---|---|---|---|---|---|---|---|
| Total costs (Int $) | ||||||||
| Universal strategy | 10,498,335 | 23,063,105 | 9,121,907 | 39,077,961 | 17,144,588 | 33,472,076 | 32,326,020 | 4,014,771 |
| Targeted strategy | 1,416,185 | 2,272,838 | 2,403,868 | 6,774,350 | 2,022,018 | 4,554,258 | 4,880,764 | 1,094,184 |
| DALY averted | ||||||||
| Universal strategy | 35 | 206 | 78 | 3,508 | 278 | 1,499 | 1,533 | 292 |
| Targeted strategy | 17 | 101 | 38 | 1,719 | 136 | 735 | 751 | 143 |
| ACER | ||||||||
| Universal strategy | 299,952 | 111,957 | 116,948 | 11,140 | 61,671 | 22,330 | 21,087 | 13,749 |
| Targeted strategy | 83,305 | 22,503 | 63,260 | 3,941 | 14,868 | 6,196 | 6,499 | 7,652 |
| Reference (3 times GDP per capita) | 10,771 | 10,838 | 13,737 | 28,440 | 32,095 | 17,052 | 23,855 | 49,933 |
| ICER | ||||||||
| Universal strategy | 504,564 | 198,003 | 167,951 | 18,057 | 106,497 | 37,851 | 35,096 | 19,601 |
| Targeted strategy | 83,305 | 22,503 | 63,260 | 3,941 | 14,868 | 6,196 | 6,499 | 7,652 |
Figure 3The relationship of the average cost-effectiveness ratio (ACER) and the proportion of benefit population for two screening strategies (universal screening and targeted screening).
Figure 4The relationship of the long-term costs saving or implementation costs of two screening strategies (universal screening and targeted screening) and the proportion of benefit population.